Pancreatic Cancer Research

ResearcherUniversity of RochesterActive in the last 2 years

Marcus Smith Noel

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-3658-6950; OpenAlex author ID A5060044072. Sources: ClinicalTrials.gov.

Their work

Papers
15 (first author 1, last author 4)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
1
Collaborators
82
Papers, trials and grants by year

2013: 1 paper · 2014: none · 2015: none · 2016: none · 2017: none · 2018: none · 2019: 1 paper · 2020: 1 paper, 1 trial · 2021: 1 paper · 2022: 5 papers · 2023: 2 papers · 2024: 2 papers · 2025: 1 paper · 2026: 1 paper

Papers 15

  1. Development and Validation of a Computational Histology Artificial Intelligence-Powered Predictive Biomarker for Selection of Chemotherapy in Advanced Pancreat… Co-author DOI 10.1200/jco-25-02199↗
  2. TRYBECA-1: A Randomized Phase III Study of Eryaspase Combined With Chemotherapy Versus Chemotherapy as Second-Line Treatment in Patients With Advanced Pancreat… Co-author DOI 10.1200/jco-25-00872↗
  3. Patterns of Failure Following Preoperative Chemotherapy and Stereotactic Body Radiation Therapy and Resection for Patients with Borderline Resectable or Locall… Co-author DOI 10.1007/s12029-023-00996-3↗
  4. Phase 1 Study of Hypofractionated Proton Beam Radiation Therapy in Adjuvant Pancreatic Cancer (PROTON-PANC). Co-author DOI 10.1016/j.ijrobp.2023.09.015↗
  5. Napabucasin plus nab-paclitaxel with gemcitabine versus nab-paclitaxel with gemcitabine in previously untreated metastatic pancreatic adenocarcinoma: an adapti… Co-author DOI 10.1016/j.eclinm.2023.101897↗
  6. Adjuvant nab-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial. Co-author DOI 10.1200/jco.22.01134↗
  7. A randomized phase II study of SM-88 plus methoxsalen, phenytoin, and sirolimus in patients with metastatic pancreatic cancer treated in the second line and be… Co-author DOI 10.1002/cam4.4768↗
  8. Cytotoxic Chemotherapy in Advanced Pancreatic Cancer. Last author DOI 10.1016/j.hoc.2022.07.006↗
  9. Anti-Ro60 Antibodies Utility as a Diagnostic Indicator of Pancreatic Cancer: A Case Report. Last author DOI 10.1097/mpa.0000000000002202↗
  10. The Next Frontier in Pancreatic Cancer: Targeting the Tumor Immune Milieu and Molecular Pathways. Last author DOI 10.3390/cancers14112619↗
  11. The Role of Immunotherapy in Pancreatic Cancer. Last author DOI 10.3390/curroncol29100541↗
  12. Randomized Phase II Study of PARP Inhibitor ABT-888 (Veliparib) with Modified FOLFIRI versus FOLFIRI as Second-line Treatment of Metastatic Pancreatic Cancer: … Co-author DOI 10.1158/1078-0432.ccr-21-1789↗
  13. Phase 1b study of a small molecule antagonist of human chemokine (C-C motif) receptor 2 (PF-04136309) in combination with nab-paclitaxel/gemcitabine in first-l… Co-author DOI 10.1007/s10637-019-00830-3↗
  14. Disparities in Pancreatic Cancer Treatment and Outcomes. Co-author DOI 10.1089/heq.2019.0057↗
  15. Unresectable locally advanced pancreatic cancer: treatment with neoadjuvant leucovorin, fluorouracil, irinotecan, and oxaliplatin and assessment of surgical re… First author DOI 10.1200/jco.2012.44.0339↗

Trials 1

  1. Eryaspase With Modified FOLFIRINOX in Advanced Pancreatic Ductal Adenocarcinoma Principal investigator NCT04292743↗

Closest collaborators

The 25 strongest of 82 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Aiwu Ruth He · 2 shared papers, 2024 · strength 0.37
  2. Emily R. Winslow · 2 shared papers, 2024 · strength 0.37
  3. Keith Robert Unger · 2 shared papers, 2024 · strength 0.37
  4. Benjamin Adam Weinberg · 2 shared papers, 2024 · strength 0.37
  5. Louis M. Weiner · 2 shared papers, 2024 · strength 0.37
  6. John Lindsay Marshall · 2 shared papers, 2024 · strength 0.37
  7. Michael Jon Pishvaian · 2 shared papers, 2021–2022 · strength 0.37
  8. Marion L. Hartley · 2 shared papers, 2022 · strength 0.37
  9. Christos K Fountzilas · 2 shared papers, 2025–2026 · strength 0.36
  10. Eric Van Cutsem · 2 shared papers, 2023–2025 · strength 0.31
  11. Ali Jaber Alqahtani · 1 shared paper, 2022 · strength 0.26
  12. Alexandra Piselli · 1 shared paper, 2022 · strength 0.26
  13. Muneeb U. Rehman · 1 shared paper, 2022 · strength 0.26
  14. Chao Yin · 1 shared paper, 2022 · strength 0.26
  15. Philip A. Philip · 2 shared papers, 2021–2022 · strength 0.25
  16. Reetu Mukherji · 1 shared paper, 2022 · strength 0.22
  17. Kevin A Fiscella · 1 shared paper, 2019 · strength 0.20
  18. Davendra P. S. Sohal · 1 shared paper, 2026 · strength 0.19
  19. Vivek U. Nimgaonkar · 1 shared paper, 2026 · strength 0.19
  20. Andrew Eugene Hendifar · 1 shared paper, 2026 · strength 0.19
  21. Barbara T. Grünwald · 1 shared paper, 2026 · strength 0.19
  22. Brent K. Larson · 1 shared paper, 2026 · strength 0.19
  23. Haochen Zhang · 1 shared paper, 2026 · strength 0.19
  24. Robert C. Grant · 1 shared paper, 2026 · strength 0.19
  25. Natalie Moshayedi · 1 shared paper, 2026 · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.